<?xml version="1.0" encoding="utf-8"?><xliff xmlns:sdl="http://sdl.com/FileTypes/SdlXliff/1.0" xmlns="urn:oasis:names:tc:xliff:document:1.2" version="1.2" sdl:version="1.0"><file original="C:\Users\134\Desktop\Translatrix\HKI_test-set_EN-FI\en-GB\en-test-1-totranslate\segment_04_en\reuters.165942.txt" datatype="x-sdlfilterframework2" source-language="en-GB" target-language="fi-FI"><header><file-info xmlns="http://sdl.com/FileTypes/SdlXliff/1.0"><value key="SDL:FileId">6fa3e560-29c2-4c41-a917-ea9de7ddea33</value><value key="SDL:CreationDate">10/24/2016 10:19:05</value><value key="SDL:OriginalFilePath">C:\Users\134\Desktop\Translatrix\HKI_test-set_EN-FI\en-GB\en-test-1-totranslate\segment_04_en\reuters.165942.txt</value><value key="SDL:OriginalEncoding">us-ascii</value><value key="SDL:AutoClonedFlagSupported">True</value><value key="HasUtf8Bom">False</value><value key="LineBreakType">
</value><value key="ParagraphTextDirections"></value><sniff-info><detected-encoding detection-level="Guess" encoding="us-ascii"/><detected-source-lang detection-level="Guess" lang="en-GB"/><props><value key="HasUtf8Bom">False</value><value key="LineBreakType">
</value></props></sniff-info></file-info><sdl:filetype-info><sdl:filetype-id>Plain Text v 1.0.0.0</sdl:filetype-id></sdl:filetype-info><tag-defs xmlns="http://sdl.com/FileTypes/SdlXliff/1.0"><tag id="0"><st name="^">^</st></tag><tag id="1"><st name="$">$</st></tag><tag id="2"><st name="^">^</st></tag><tag id="3"><st name="$">$</st></tag><tag id="4"><st name="^">^</st></tag><tag id="5"><st name="$">$</st></tag><tag id="6"><st name="^">^</st></tag><tag id="7"><st name="$">$</st></tag><tag id="8"><st name="^">^</st></tag><tag id="9"><st name="$">$</st></tag><tag id="10"><st name="^">^</st></tag><tag id="11"><st name="$">$</st></tag></tag-defs></header><body><trans-unit translate="no" id="5b851de0-2dc0-4f76-ae04-c66f4890cd56"><source><x id="0"/></source></trans-unit><trans-unit id="f521d8ea-cf4e-4f69-8ca6-021217ca3331"><source>Gilead to get attorney fees in hepatitis C patent fight with Merck</source><seg-source><mrk mtype="seg" mid="1">Gilead to get attorney fees in hepatitis C patent fight with Merck</mrk></seg-source><target><mrk mtype="seg" mid="1">Gileadille korvataan asianajajakulut hepatiitti C -patenttitaistelussa Merckia vastaan</mrk></target><sdl:seg-defs><sdl:seg id="1" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">LXjGUVl2BXHUUjeNypZfAlL8lMI=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/17/2017 08:20:38</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/17/2017 08:20:38</sdl:value><sdl:value key="SDL:OriginalTranslationHash">2046825954</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="eef78f40-3499-4e88-b9ab-e96a9899c9b8"><source><x id="1"/>
<x id="2"/></source></trans-unit><trans-unit id="ff2d7753-0631-48b9-a013-f86a8b7a5503"><source>Gilead Sciences Inc is entitled to receive the attorney fees it incurred related to hepatitis C patent litigation with drugmaker Merck &amp; Co Inc, a U.S. district judge has ruled.</source><seg-source><mrk mtype="seg" mid="2">Gilead Sciences Inc is entitled to receive the attorney fees it incurred related to hepatitis C patent litigation with drugmaker Merck &amp; Co Inc, a U.S. district judge has ruled.</mrk></seg-source><target><mrk mtype="seg" mid="2">Yhdysvaltain kihlakunnantuomari on määrännyt, että Gilead Sciences Inc on oikeutettu saamaan asianajajakulut, joita sille aiheutui hepatiitti C -potilasta koskevassa riitajutussa lääkevalmistaja Merck &amp; Co Inciä vastaan.</mrk></target><sdl:seg-defs><sdl:seg id="2" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">DjTyh2ATCUwaZVopivtmPP8ZLuw=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/17/2017 08:30:48</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/17/2017 08:41:42</sdl:value><sdl:value key="SDL:OriginalTranslationHash">102490002</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="e9c13dcc-fcaf-4766-8fcc-3f340d95ea34"><source><x id="3"/>
<x id="4"/></source></trans-unit><trans-unit id="7d52fb6e-b903-4aec-9a03-e7247a9e8db8"><source>In June, Gilead was freed from paying up $200 million in damages for infringing two Merck patents related to Gilead&apos;s blockbuster drugs Sovaldi and Harvoni, after a U.S. judge found a pattern of misconduct by Merck including lying under oath and other unethical practices.</source><seg-source><mrk mtype="seg" mid="3">In June, Gilead was freed from paying up $200 million in damages for infringing two Merck patents related to Gilead&apos;s blockbuster drugs Sovaldi and Harvoni, after a U.S. judge found a pattern of misconduct by Merck including lying under oath and other unethical practices.</mrk></seg-source><target><mrk mtype="seg" mid="3">Kesäkuussa Gilead vapautettiin 200 miljoonan dollarin maksuista heidän rikottuaan kahta Merckin patenttia, jotka liittyivät Gileadin menestyslääkkeisiin Sovaldiin ja Harvoniin. Tämä vapautus seurasi sitä, kun yhdysvaltalainen tuomari löysi Merckin väärinkäytöksiä, joihin kuului väärä vala ja muita epäeettisiä käytäntöjä.</mrk></target><sdl:seg-defs><sdl:seg id="3" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">h1tmsLKqkbb434/v08+duTFZWhA=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/17/2017 08:40:26</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/17/2017 08:40:26</sdl:value><sdl:value key="SDL:OriginalTranslationHash">1196641973</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="6f373f70-7c30-42ec-8c75-e33c0c452a98"><source><x id="5"/>
<x id="6"/></source></trans-unit><trans-unit id="0a61de07-d782-424c-a5f2-d1e77027eabf"><source>In a filing on Thursday, U.S. District Judge Beth Labson Freeman said that Gilead was entitled to relief from the fees it incurred while defending the case.</source><seg-source><mrk mtype="seg" mid="4">In a filing on Thursday, U.S. District Judge Beth Labson Freeman said that Gilead was entitled to relief from the fees it incurred while defending the case.</mrk></seg-source><target><mrk mtype="seg" mid="4">Torstaina jätetyssä tuomiossa Yhdysvaltain kihlakunnantuomari Beth Labson Freeman sanoi, että Gilead on oikeutettu vapautumaan korvauksista, joita sille aiheutui kannetta vastustaessa.</mrk></target><sdl:seg-defs><sdl:seg id="4" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">YnANPHKKV7pxe8AeabSJon78OyQ=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/17/2017 08:42:54</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/17/2017 08:42:54</sdl:value><sdl:value key="SDL:OriginalTranslationHash">1063022291</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="6f648c05-2875-4a40-a758-6eea8883f7b1"><source><x id="7"/>
<x id="8"/></source></trans-unit><trans-unit id="745623fa-78b2-406c-892f-563ef9e8c996"><source>Merck is trying to catch up to Gilead, which dominates the market on a new generation of hepatitis C drugs that can cure well over 90 percent of patients with the liver disease.</source><seg-source><mrk mtype="seg" mid="5">Merck is trying to catch up to Gilead, which dominates the market on a new generation of hepatitis C drugs that can cure well over 90 percent of patients with the liver disease.</mrk></seg-source><target><mrk mtype="seg" mid="5">Merck yrittää saada kiinni Gileadin, joka hallitsee markkinoita uudella hepatiitti C -lääkkeiden sukupolvella, joka voi parantaa selvästi yli 90 prosenttia potilaista, joilla on tämä maksasairaus.</mrk></target><sdl:seg-defs><sdl:seg id="5" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">DIqVK05EDa20HLoItst0gZulm8k=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/17/2017 08:43:39</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/17/2017 08:43:39</sdl:value><sdl:value key="SDL:OriginalTranslationHash">1339373653</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="3a24bb19-16cd-4652-8b13-601a6c733d49"><source><x id="9"/>
<x id="10"/></source></trans-unit><trans-unit id="243d9ad1-fbf7-47e3-bcdf-b5dcd9261cb7"><source>The case dates back to 2013 when Gilead and Merck sued each other, claiming ownership of laboratory work underlying sofosbuvir, the active ingredient in Gilead&apos;s drugs.</source><seg-source><mrk mtype="seg" mid="6">The case dates back to 2013 when Gilead and Merck sued each other, claiming ownership of laboratory work underlying sofosbuvir, the active ingredient in Gilead&apos;s drugs.</mrk></seg-source><target><mrk mtype="seg" mid="6">Oikeusjuttu juontuu vuoteen 2013, kun Gilead ja Merck haastoivat toisensa oikeuteen Gileadin lääkkeiden tehoaine sofosbuvirin pohjalla olevan laboratoriotyön omistajuudesta.</mrk></target><sdl:seg-defs><sdl:seg id="6" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">SBGe/lYPy7S4dy6q0VRAVgEBSjo=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/17/2017 08:46:59</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/17/2017 08:46:59</sdl:value><sdl:value key="SDL:OriginalTranslationHash">-143749135</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="a52571d8-bc05-40b5-a2a6-7847b183b6e0"><source><x id="11"/>
</source></trans-unit></body></file></xliff>